
---
title: "0968 GILD"
subtitle: "Stock Analysis by ChatGPT"
date: 2023-08-06T11:33:53
draft: true
tags: ['Gilead Sciences, Inc.', 'GILD', 'Pharmaceutical Industry', 'HIV Drugs', 'Oncology']
author: Friday Wall
---

score:968
### Chances:
1. Gilead Sciences expects a third of sales to come from its cancer treatments by 2030, which could drive future growth.
2. Gilead Sciences has a rich portfolio of therapies for life-threatening infectious diseases, including pulmonary and cardiovascular diseases and cancer.
3. The company's CEO mentioned that Gilead is overperforming significantly, excluding one-time items, indicating positive performance.
4. Gilead Sciences raised its full-year revenue forecast, showing potential growth opportunities.
5. Gilead Sciences' strong performance in HIV drugs and oncology contributed to beating revenue estimates.
### Risks:
1. Gilead Sciences' Q2 earnings missed on litigation charges, which could impact the company's financial performance.
2. The company reported lower second-quarter profit due to costs from a legal settlement and lower sales of its COVID-19 treatment.
3. Gilead Sciences delivered negative earnings and revenue surprises in the quarter, which may raise concerns among investors.
4. The company's estimate for COVID antiviral Veklury was trimmed due to lower pandemic-related hospitalizations, which could affect future earnings.
5. The COVID-19 pandemic's impact on Gilead Sciences' sales and treatments may pose risks for the company's performance.
### Score:968
chances characters count - risks characters count = -32

investment score = 1000 + chances characters count - risks characters count
### References:
- 2023-08-06 [Gilead Sciences, Inc.'s (NASDAQ:GILD) Intrinsic Value Is Potentially 68% Above Its Share Price](https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-110047502.html?.tsrc=rss)
- 2023-08-05 [Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030](https://finance.yahoo.com/m/f3eebbe7-87e3-3577-8743-570fd581460d/gilead-plots-a-massive-move.html?.tsrc=rss)
- 2023-08-05 [Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology](https://finance.yahoo.com/news/gileads-gild-q2-earnings-miss-170000213.html?.tsrc=rss)
- 2023-08-05 [Is Gilead Sciences (GILD) Fairly Valued? An In-Depth Analysis](https://finance.yahoo.com/news/gilead-sciences-gild-fairly-valued-163533453.html?.tsrc=rss)
- 2023-08-04 [Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript](https://finance.yahoo.com/m/00c660dd-eab1-3656-8718-f779ecaaabc3/gilead-sciences-%28gild%29-q2.html?.tsrc=rss)
- 2023-08-04 [Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates](https://finance.yahoo.com/news/gilead-gild-q2-earnings-key-230007906.html?.tsrc=rss)
- 2023-08-04 [Gilead Sciences (GILD) Q2 Earnings Lag Estimates](https://finance.yahoo.com/news/gilead-sciences-gild-q2-earnings-214513264.html?.tsrc=rss)
- 2023-08-04 [UPDATE 1-Gilead quarterly profit falls on COVID sales drop, legal settlement charge](https://finance.yahoo.com/news/1-gilead-quarterly-profit-falls-205317434.html?.tsrc=rss)
- 2023-08-04 [Gilead Sciences Cuts Profit Forecast on Legal Settlement](https://finance.yahoo.com/m/84b06786-0450-3b56-9982-d1857b10ede3/gilead-sciences-cuts-profit.html?.tsrc=rss)
- 2023-08-04 [Gilead quarterly profit falls on COVID sales drop, legal settlement charge](https://finance.yahoo.com/news/gilead-quarterly-profit-falls-covid-200514004.html?.tsrc=rss)


                